Lyell, Verve IPOs raise a combined $692M as both biotechs steer toward clinical trials June 17, 2021 Auto Bot BioPharma, biopharma nl, biotech IPO, Cambridge, cancer, cardiovascular disease, Clinical Trials, Massachusetts, Pharma, South San Francisco 0 Lyell Immunopharma and Verve Therapeutics are still preclinical, but they’re bring novel genetic approaches to the treatment of cancer and cardiovascular disease. Now the two companies can claim two of the biggest biotech IPOs of 2021 so far.